The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Sangamo Therapeutics Inc’s stock clocked out at $0.56, up 6.48% from its previous closing price of $0.52. In other words, the price has increased by $6.48 from its previous closing price. On the day, 1.18 million shares were traded. SGMO stock price reached its highest trading level at $0.5591 during the session, while it also had its lowest trading level at $0.52.
Ratios:
To gain a deeper understanding of SGMO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.40.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, RBC Capital Mkts on November 03, 2023, Downgraded its rating to Sector Perform and sets its target price to $2 from $6 previously.
On April 28, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $5 to $1.50.
Wedbush Upgraded its Neutral to Outperform on February 27, 2023, while the target price for the stock was maintained at $16.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 26 ’23 when BIOGEN INC. sold 6,000,000 shares for $0.50 per share. The transaction valued at 3,000,000 led to the insider holds 17,652,466 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 115326280 and an Enterprise Value of 56538148. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.64 while its Price-to-Book (P/B) ratio in mrq is 1.19. Its current Enterprise Value per Revenue stands at 0.321 whereas that against EBITDA is -0.647.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.33, which has changed by -0.59055114 over the last 52 weeks, in comparison to a change of 0.22379243 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $1.67, while it has fallen to a 52-week low of $0.29. The 50-Day Moving Average of the stock is -23.61%, while the 200-Day Moving Average is calculated to be -19.84%.
Shares Statistics:
It appears that SGMO traded 2.40M shares on average per day over the past three months and 1138830 shares per day over the past ten days. A total of 203.67M shares are outstanding, with a floating share count of 183.15M. Insiders hold about 10.07% of the company’s shares, while institutions hold 46.10% stake in the company. Shares short for SGMO as of 1713139200 were 13246447 with a Short Ratio of 5.52, compared to 1710460800 on 10884464. Therefore, it implies a Short% of Shares Outstanding of 13246447 and a Short% of Float of 6.419999999999999.
Earnings Estimates
As of right now, 8.0 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.27, while EPS last year was $0.12. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.08 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.23 and -$0.77 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is -$0.27, with 8.0 analysts recommending between $0.28 and -$0.64.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $6.65M. It ranges from a high estimate of $11.3M to a low estimate of $2M. As of the current estimate, Sangamo Therapeutics Inc’s year-ago sales were $157.96MFor the next quarter, 6 analysts are estimating revenue of $8.24M. There is a high estimate of $17.8M for the next quarter, whereas the lowest estimate is $2M.
A total of 7 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $95M, while the lowest revenue estimate was $13.8M, resulting in an average revenue estimate of $45.88M. In the same quarter a year ago, actual revenue was $176.23MBased on 8 analysts’ estimates, the company’s revenue will be $79.01M in the next fiscal year. The high estimate is $229M and the low estimate is $26.4M.
